UBTECH Humanoid Robot Walker S2 Begins Mass Production and Delivery, with Orders Exceeding 800 Million Yuan

SHENZHEN, China, Nov. 17, 2025 /PRNewswire/ -- UBTECH has begun mass production and delivery of the first batch of several hundred full-size industrial humanoid robots, Walker S2, which will be deployed in phases across frontline industrial applications. This milestone moves the company toward its target of delivering 500 units within the year and marks the beginning of large-scale, real-world implementation of humanoid robotics.

 
UBTECH Walker S2 - World’s First Mass Delivery of Humanoid Robots

 

By establishing a closed-loop commercial cycle—from technology and real-world application to delivery and iterative improvement—UBTECH has developed core capabilities to rapidly address market demands and efficiently secure and fulfill orders, setting a replicable benchmark for the deployment of humanoid robots. The start of mass delivery highlights UBTECH's expanding ability to strengthen and re-configure industrial ecosystems, accelerating the industry's shift toward global, high-quality, scaled deployment.

Amid rising market demand, UBTECH has outlined a clear production ramp-up plan, targeting an annual capacity of 5,000 industrial humanoid robots by 2026, scaling to 10,000 units by 2027. UBTECH is already supplying its Walker S2 robots for key industrial uses in automotive manufacturing, smart factories, intelligent logistics, and data collection centers.

UBTECH has also taken the lead in shifting its delivery approach from providing products to delivering full operational capabilities, introducing a first-of-its-kind, standardized and replicable turnkey solution. With UBTECH's proprietary BrainNet technology platform, these solutions enable rapid scenario deployment, enhance usability for industrial customers, and support innovative applications across manufacturing environments. Walker S2 is the world's first industrial humanoid robot integrated with Co-Agent—UBTECH's proprietary intelligent agent system. This system empowers the robot with closed-loop operational capabilities, including intention understanding, task planning, tool usage, and autonomous anomaly detection and handling. Complemented by a comprehensive user-training system, this shift from product delivery to scenario-based enablement offers a practical pathway to large-scale adoption of humanoid robots.

Since early 2025, UBTECH's Walker series humanoid robots have accumulated orders exceeding 800 million yuan (approx. US$112 million), reinforcing the company's leadership in global humanoid robot commercialization. Among these, a recent contract to deploy Walker S2 robots at a data collection center in Zigong, valued at 159 million yuan, ranks as the second-largest order of the year, following a record 250 million yuan order secured in September. These accomplishments reflect growing market demand and strong industry recognition of UBTECH's product capabilities.

UBTECH collaborates with leading industry players including BYD, Dongfeng Liuzhou Motor, Geely Auto, FAW-Volkswagen Qingdao, Audi FAW, BAIC New Energy, Foxconn, and SF Express. Furthermore, with the Walker S series now entered on a wide range of automotive production lines to complete different tasks, UBTECH continues to accumulate extensive real-world data and frontline operational experience. This continuous scenario-based practice is essential for optimizing product performance and enables the development of production-line-ready, task-driven swarm intelligence.

Humanoid robots, recognized as the ultimate form of embodied intelligence, now stand at a historic inflection point—evolving from technological prototypes toward industrial-scale deployment. To achieve real-world commercialization in the age of embodied intelligence, the industry must overcome three fundamental challenges: technological maturity, real-world application, and scalable delivery. As the world's first company to complete the loop between technological validation and commercial deployment in industrial environments, UBTECH is executing a proven strategy: advancing core technologies to support field deployment, using real-world insights to refine delivery models, and expanding scaled delivery to drive continuous technological evolution. UBTECH is committed to collaborating with industry partners to build an open, collaborative ecosystem and advance toward the large-scale adoption of humanoid robotics.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

UBTECH Humanoid Robot Walker S2 Begins Mass Production and Delivery, with Orders Exceeding 800 Million Yuan

UBTECH Humanoid Robot Walker S2 Begins Mass Production and Delivery, with Orders Exceeding 800 Million Yuan

UBTECH Humanoid Robot Walker S2 Begins Mass Production and Delivery, with Orders Exceeding 800 Million Yuan

• 104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion
• Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027
• First-in-class PRS inhibitor being developed as a potential new therapeutic option for IPF

BARCELONA, Spain and SEOUL, South Korea, Sept. 24, 2026 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented a poster on the baseline characteristics of all 104 patients enrolled in the global Phase 2 clinical trial of its idiopathic pulmonary fibrosis (IPF) drug candidate 'Bersiporocin (DWN12088)' at the European Respiratory Society (ERS) Congress 2026, held on September 6 (local time) in Barcelona, Spain.

Idiopathic Pulmonary Fibrosis is a disease in which various inflammatory and fibrotic signals interact, leading to excessive production and accumulation of collagen. Bersiporocin, being developed by Daewoong Pharmaceutical, selectively inhibits prolyl-tRNA synthetase (PRS), thereby reducing excessive collagen production associated with fibrosis.

Bersiporocin has a differentiated mechanism of action that targets collagen synthesis downstream of multiple profibrotic signals through PRS inhibition. Based on this distinct mechanism, it is being evaluated both in patients receiving background antifibrotic therapy and in those not receiving such treatment.

This presentation analyzed the baseline clinical and functional characteristics of all IPF patients recruited in South Korea and the United States. Following the presentation of interim enrollment data at KATRDIC 2025, Daewoong Pharmaceutical presented baseline data from the fully enrolled study population for the first time at ERS 2026.

The analysis showed that of the total 104 patients, 55 (52.9%) were from South Korea and 49 (47.1%) from the US. A total of 71 patients (68.3%) were receiving background antifibrotic therapy, while 33 patients (31.7%) were not. Mean forced vital capacity (FVC) was approximately 77% predicted, while mean diffusing capacity of the lungs for carbon monoxide (DLCO) was approximately 51% predicted. Overall, baseline clinical and functional characteristics were generally similar between patients with and without background antifibrotic therapy.

The ongoing global Phase 2 study is a randomized, double-blind, placebo-controlled trial taking place in South Korea and the US. Patients receive either Bersiporocin or a placebo twice daily for 24 weeks, with concomitant use of pirfenidone or nintedanib permitted. The study design reflects real-world IPF treatment settings by including patients both with and without background antifibrotic therapy.

This baseline analysis provides important context for interpreting the Phase 2 efficacy and safety results. Daewoong Pharmaceutical plans to announce top-line Phase 2 results in the first half of 2027.

Meanwhile, Bersiporocin has received Orphan Drug Designation and Fast Track status from the US FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA), driving its global development forward.

Professor Moo Suk Park of the Department of Pulmonology at Severance Hospital, who participated in the study, said, "This study provides a comprehensive overview of the baseline characteristics of 104 IPF patients enrolled in South Korea and the US. As the study includes patients both with and without background antifibrotic therapy, these baseline data will provide important context for interpreting the efficacy and safety outcomes of Bersiporocin."

Seongsoo Park, CEO of Daewoong Pharmaceutical, stated, "Successfully completing enrollment for the global Phase 2 trial and sharing the full baseline patient profile at ERS 2026 marks a significant milestone in Bersiporocin's development. We will continue to advance the program toward top-line Phase 2 results in H1 2027 and use these findings to inform subsequent global development."

[Reference]

https://drive.google.com/file/d/1XSXImvc5mcgdoSozP_B4BnDlsTW7Pfz_/view 
Link to the poster: 'Baseline Clinical and Functional Spectrum of Idiopathic Pulmonary Fibrosis Patients in a Fully Enrolled Global Phase 2 Trial of the PRS Inhibitor Bersiporocin'

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026